Rein Therapeutics Inc. (RNTX)
1.89
0.06 (3.28%)
At close: Apr 25, 2025, 3:59 PM
1.91
1.33%
After-hours: Apr 25, 2025, 04:00 PM EDT
3.28% (1D)
| Bid | 1.78 |
| Market Cap | 41.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.51 |
| PE Ratio (ttm) | -0.54 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.98 |
| Volume | 65,521 |
| Avg. Volume (20D) | 50,543 |
| Open | 1.79 |
| Previous Close | 1.83 |
| Day's Range | 1.82 - 1.92 |
| 52-Week Range | 1.35 - 5.18 |
| Beta | 2.12 |
About RNTX
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 c...
Industry Medical - Pharmaceuticals
Sector Healthcare
IPO Date Jun 29, 2017
Employees 11
Stock Exchange NASDAQ
Ticker Symbol RNTX
Website http://www.reintx.com